Table 1.
Characteristics of patients with AML who received 6–7/8 HLA-matched transplants
| KIR Ligand Matched |
KIR Ligand Mismatched |
P-value | |
|---|---|---|---|
| Total number | 114 | 85 | |
| Gender | 0.68 | ||
| Male | 53 (46%) | 37 (44%) | |
| Female | 61 (54%) | 48 (56%) | |
| Age, years | 0.87 | ||
| ≤ 16 | 82 (72%) | 62 (73%) | |
| > 16 | 32 (28%) | 23 (27%) | |
| Cytomegalovirus serostatus | 0.38 | ||
| Positive | 66 (58%) | 44 (52%) | |
| Negative | 41 (36%) | 38 (45%) | |
| Not reported | 7 (6%) | 3 (4%) | |
| Disease status at transplantation | 0.41 | ||
| 1st Complete remission | 39 (34%) | 37 (44%) | |
| 2nd Complete remission | 36 (32%) | 23 (27%) | |
| Relapse | 39 (34%) | 25 (29%) | |
| Unit total nucleated cell dose | 0.79 | ||
| <3 × 107/kg | 17 (15%) | 10 (12%) | |
| ≥3 × 107/kg | 95 (83%) | 73 (86%) | |
| Unknown | 2 (2%) | 2 (2%) | |
| Donor-recipient HLA-match A/B low resolution, DRB1 |
0.22 | ||
| 6/6 HLA-match | 22 (19%) | 12 (14%) | |
| 5/6 HLA-match | 81 (71%) | 69 (81%) | |
| 4/6 HLA-match | 11 (10%) | 4 (5%) | |
| Donor-recipient allele-level HLA-match A/B/C/DRB1* |
<0.001 | ||
| 7/8 HLA-match | 65 (57%) | 15 (18%) | |
| 6/8 HLA-match | 49 (43%) | 70 (82%) | |
| In vivo T-cell depletion | 0.66 | ||
| Yes | 78 (68%) | 62 (73%) | |
| No | 33 (29%) | 22 (26%) | |
| Not reported | 3 (3%) | 1 (1%) | |
| Conditioning regimen | 0.70 | ||
| TBI containing regimens | 46 (40%) | 32 (38%) | |
| Non-TBI regimens | 68 (60%) | 53 (62%) | |
| Transplant period | 0.44 | ||
| 2000 – 2004 | 28 (25%) | 25 (29%) | |
| 2005 – 2010 | 86 (75%) | 60 (71%) | |
| Follow-up, surviving patients | |||
| Median (range), months | 40 (9 – 120) | 48 (13 – 100) |
*KIR ligand matched HCT: N=6 single mismatch at HLA-C locus and N=1 double mismatch at HLA-C loci. Additional mismatches at HLA-C locus occurred with mismatches at HLA-A (N=6), HLA-B (N=11) and HLA-DRB1 (N=6)
*KIR ligand mismatched HCT: N=2 single mismatch at HLA-C locus and N=1 double mismatch at HLA-C loci. Additional mismatches at HLA-C locus occurred with mismatches at HLA-A (N=7), HLA-B (N=13) and HLA-DRB1 (N=5)